Diarrhea News and Research

Latest Diarrhea News and Research

NIH awards UNC researcher $507,000 for rotavirus vaccine study

A University of North Carolina at Chapel Hill researcher has been awarded a four-year, $507,000 grant from the National Institute of Health's Fogarty International Center to study the effectiveness of rotavirus vaccines in the Central American nation of Nicaragua.

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Used hotel soaps help prevent disease in developing countries

The Associated Press/Washington Post profiled the efforts of Atlanta-based Derreck Kayongo, a Ugandan "anti-poverty advocate." Kayongo has launched "the Global Soap Project, an effort to help his country's poorest - one used bar of hotel soap at a time," the AP/Washington Post writes.

14 Oct 2009

Human milk oligosaccharides protect infants against infection

Human milk oligosaccharides - an important ingredient in human breast milk - play a central role in protecting infants against infection. An innovative process developed by Jennewein Biotechnologie GmbH allows for the first time ever the production of these scarce sugar molecules for use as an ingredient in baby food and in additional food products.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

News outlets examine efforts to improve sanitation worldwide

The Washington Post examines how the "No Toilet, No Bride" campaign in India is helping to increase access to home toilets in rural India. According to the newspaper, "About 665 million people in India -- about half the population -- lack access to latrines." Yet, since the campaign launched two years ago, "1.4 million toilets have been built here in the northern state of Haryana, some with government funds, according to the state's health department" - a movement that women's rights activists hail as "a revolution."

12 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

AP examines H1N1 surveillance by U.S., WHO

The Associated Press examines how the decision by U.S. health officials to stop counting new cases of H1N1 (swine flu) in July has complicated the government's ability to assess groups particularly hard hit by the virus.

9 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

FDA files complaint against Rel's Foods for selling adulterated food products

The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.

9 Oct 2009

Countries make little progress in implementing life-saving techniques to treat children with diarrhea

Despite evidence that low-cost diarrhea treatments such as lower osmolarity oral rehydration salts (ORS) and zinc supplements could drastically reduce the number of deaths among children, little progress has been made in implementing these life-saving techniques, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

9 Oct 2009

Biocodex secures consumer distribution with CVS stores nationwide for its Florastor

As part of its continued expansion throughout the U.S. retail market, Biocodex, Inc., the U.S. arm of the French manufacturer of Florastor® and Florastor® Kids, has secured consumer distribution with CVS stores nationwide beginning this month. Florastor will be placed on-shelf in the stomach/digestives aisle, while Florastor Kids will be available upon request “behind the counter.”

8 Oct 2009

Napo Pharmaceuticals hosts educational panel to address global health and environment

Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights.

8 Oct 2009

U.N. appeals for $74m to provide emergency assistance in the Philippines; health-effects of other natural disasters

The U.N. on Tuesday launched an appeal for $74 million "to provide emergency assistance to hundreds of thousands of victims of two catastrophic typhoons that have struck the Philippines in less than two weeks," VOA News reports (Schlein, 10/6).

8 Oct 2009

Gen-Probe to acquire Prodesse for $60 million in cash

Gen-Probe Incorporated announced today that it has signed a definitive agreement to acquire Prodesse, Inc., a privately held leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Diarrhea News and Research

Latest Diarrhea News and Research

NIH awards UNC researcher $507,000 for rotavirus vaccine study

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Used hotel soaps help prevent disease in developing countries

Human milk oligosaccharides protect infants against infection

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

News outlets examine efforts to improve sanitation worldwide

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Santarus and Norgine enter into a licensing agreement for ZEGERID products

FDA approves Berinert for the treatment of hereditary angioedema

AP examines H1N1 surveillance by U.S., WHO

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

FDA files complaint against Rel's Foods for selling adulterated food products

Countries make little progress in implementing life-saving techniques to treat children with diarrhea

Biocodex secures consumer distribution with CVS stores nationwide for its Florastor

Napo Pharmaceuticals hosts educational panel to address global health and environment

U.N. appeals for $74m to provide emergency assistance in the Philippines; health-effects of other natural disasters

Gen-Probe to acquire Prodesse for $60 million in cash

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in